Page 250«..1020..249250251252..260270..»

1st synthetic mouse embryos complete with beating hearts and brains created with no sperm, eggs or womb – Livescience.com

Posted: August 5, 2022 at 2:34 am

For the first time, scientists have created mouse embryos in the lab without using any eggs or sperm and watched them grow outside the womb. To achieve this feat, the researchers used only stem cells and a spinning device filled with shiny glass vials.

The experiment is a "game changer," Alfonso Martinez Arias, a developmental biologist at Pompeu Fabra University in Barcelona who was not involved in the research, told The Washington Post (opens in new tab).

"This is an important landmark in our understanding of how embryos build themselves," he said.

The breakthrough experiment, described in a report published Monday (Aug. 1) in the journal Cell (opens in new tab), took place in a specially designed bioreactor that serves as an artificial womb for developing embryos. Within the device, embryos float in small beakers of nutrient-filled solution, and the beakers are all locked into a spinning cylinder that keeps them in constant motion. This movement simulates how blood and nutrients flow to the placenta. The device also replicates the atmospheric pressure of a mouse uterus, according to a statement (opens in new tab) from the Weizmann Institute of Science in Israel, where the research was conducted.

In a previous experiment, described in the journal Nature (opens in new tab) in 2021, the team used this bioreactor to grow natural mouse embryos, which reached day 11 of development in the device. "That really showed that mammalian embryos can grow outside the uterus its not really patterning or sending signals to the embryo so much as providing nutritional support," Jacob Hanna, an embryonic stem cell biologist at the Weizmann and senior author of both studies, told STAT News (opens in new tab)

Related: 'First complete models' of a human embryo made in the lab

After their initial success with natural embryos, the researchers wanted to try their hand at growing lab-made embryos in the mechanical womb.

To do so, they applied a chemical treatment to mouse stem cells that "reset" them into a naive state from which they could morph into any type of cell heart, liver, brain or otherwise. In a fraction of these naive cells, the team applied additional treatments to switch on genes required to make the placenta, and in a third group of cells they applied treatments to switch on the genes to make the yolk sac. "We gave these two groups of cells a transient push to give rise to extraembryonic tissues that sustain the developing embryo," Hanna said in the statement.

The scientists then placed these three groups of stem cells into the artificial womb to mix and mingle. The three flavors of cells soon came together to form clumps, but only about 50 out of 10,000 cellular clumps continued to develop into embryo-like structures and those that did only survived in the bioreactor for 8.5 days.

Over the course of those 8.5 days or nearly half of a typical mouse pregnancy the initially spherical embryos stretched out and became cylindrical, as would be expected of natural embryos, STAT News reported. The beginnings of the central nervous system began to emerge by day 6 and soon gave rise to a tiny, wrinkled brain. By day 8, the embryos had developed intestinal tracts and small, beating hearts that pushed blood stem cells through newly formed vessels.

The shape of internal structures and gene structure in the synthetic embryos differed slightly from those found in natural mouse embryos, the team noted.

In follow-up experiments, the researchers plan to study the chemical cues that push embryonic cells to become one type of tissue over another. What forces nudge certain stem cells to congregate and form the neural tube while others end up differentiating into the cells that line the intestines?

"Our next challenge is to understand how stem cells know what to do how they self-assemble into organs and find their way to their assigned spots inside an embryo," Hanna said in the statement. "And because our system, unlike a womb, is transparent, it may prove useful for modeling birth and implantation defects of human embryos."

In addition to serving as a research model, the artificial womb could also someday serve as an incubator for cells, tissues and organs grown for transplant procedures, he said.

"This is just one step, but a very important step for us to be able to study early development," Paul Tesar, a developmental biologist at Case Western Reserve University School of Medicine who was not involved in the study, told STAT News. "We're crossing into the realm of being able to generate an embryo from scratch, and potentially a living organism. Its been a really notable switch for the field."

Of course, such research comes with heavy ethical considerations.

"The mouse is a starting point for thinking about how one wants to approach this in humans," Alex Meissner, a stem cell biologist at the Max Planck Institute for Molecular Genetics, told The Washington Post. "It's not necessary to be alarmed or raise any panic, but as we learn, it's important to have in parallel the discussion: How far do we want to take it?"

Originally published on Live Science.

Read the rest here:
1st synthetic mouse embryos complete with beating hearts and brains created with no sperm, eggs or womb - Livescience.com

Posted in Molecular Genetics | Comments Off on 1st synthetic mouse embryos complete with beating hearts and brains created with no sperm, eggs or womb – Livescience.com

Researchers crack 30-year-old mystery of odour switching in worms – University of Toronto

Posted: August 5, 2022 at 2:34 am

Soil-dwelling nematodesdepend on their sophisticated sense of smell for survival,able to distinguish between more than a thousand different scents but the molecular mechanism behind their olfaction has baffled scientists for decades.

Now, researchers at the University of Toronto'sTerrence Donnelly Centre for Cellular & Biomolecular Research appear to have solved the long-standing mystery and the implications of their findings stretch beyond nematode olfaction, perhaps offering insights into how thehuman brainfunctions.

Derek van der Kooy,a professor of molecular genetics at the Donnelly Centre in the Temerty Faculty of Medicine, led a research team that uncovered the molecular mechanism behind the worms' sense of smell, suggesting that it involves a conserved protein that helps equilibrate vision in humans.

The van der Kooy lab is renowned for its neuroscience research that uses a variety of model organisms, including the nematodeCaenorhabditis elegans.

The researchers' study was published in the Proceedings of the National Academy of Sciences (PNAS) last week.

The worms have an incredible sense of smell its absolutely amazing, saysDaniel Merritt, a first co-author on the paper and recentPhD graduate who workedin the van der Kooy lab.

They can detect a very wide variety of compounds, such as molecules released from soil, fruit, flowers andbacteria. They can even smell explosives and cancer biomarkers in the urine of patients, he adds.

C. elegansare champion sniffers thanks to their 1,300 odorant receptors. As in humans, who possess a mere 400 receptors, each receptor is dedicated to sensing one type of smell but that's where the similarities end.

Human noses are lined with hundreds of sensory neurons, each expressing only one receptor type. When an odorant activates a given neuron, the signal travels deeper into the brain along its long process, or axon, where it is perceived as smell. Smell discrimination is enabled by a physical separation of axonal cables carrying different smell signals.

The worms, however, have only 32 olfactory neurons, which hold all of their 1,300 receptors.

Clearly, the one-neuron-one-smell strategy is not going to work here, Merritt says.

Yet, the worms can discriminate between different smells sensed by the same neuron. Pioneering research from the early 1990s showed that when exposed to two attractive odours, where one is uniformly present and the other is localized, the worms crawl towards the latter. But how this behaviour is regulated at the molecular level remained unclear.

It seems that all the information that is sensed by this neuron gets compressed into one signal, and yet the worm can somehow tell the difference between the upstream components. Thats where we came to it, Merritt says.

Merritt and former masters of science graduateIsabel MacKay-Clackett, a co-first author on the paper, reasoned that perhaps the worms are sensinghow strongthe smells are.

According to their hypothesis, the smells that are everywhere are not the most informative cues and would become desensitized in some way, meaning the worms would ignore them. This would leave the weakly present smells, which might be more useful in guiding behaviour, able to activate their receptors and cause signal transduction.

They also had a hunch for how this could work at the molecular level. A protein named arrestin is a well-established desensitizer of the so-called G protein coupled receptors (GPCRs), a large family of proteins that perceive external stimuli, which odorant receptors belong to. Arrestins for example allow us to adjust vision in bright light by damping down signalling through the photon-sensing receptors in the retina.

The team wondered if arrestin might also act in worms to desensitize receptors for a stronger smell in favour of those for a weaker one, when both are sensed by the same neuron. To test their hypothesis, they exposed the worms lacking the arrestin gene to two different attractive smells in a Petri dish. They mixed one smell into the agar medium to make it uniform, and put the worms on top. The other smell was placed at one spot some distance from the worms.

Without arrestin, the worms were no longer able find the source of the weaker smell. Like in the human eye squinting in bright sunshine, arrestin helps remove an overpowering sensation ambient smell in this case so that the worms can sense a localized smell and move towards it, MacKay-Clackett says.

Arrestin is not required, however, when the smells are sensed with different neurons, suggesting that the worms employ the same discrimination strategy as the vertebrates when the smell signals travel down different axons.

The team looked at different sets of smells and neurons and found they all obeyed the same logic, Merritt says. They also used drugs to block arrestin and found that this too abolished smell discrimination.

The finding is significant because it is the first evidence showing that arrestin can fine tune multiple sensations.

There is no case known in biology before this where arrestin is being used to allow for discrimination of signals external to the cell, Merritt says.

He adds that the same mechanism could be playing out in other animals when multiple GPCRs are expressed on the same cell, especially in the brain. Our brains are bathed in neurochemicals that signal through hundreds of different GPCRs, raising a possibility that arrestin, of which there are four types in humans, could be key for information processing.

Our work provides one piece of puzzle how the worms amazing sense of smell works, but it also informs our understanding of how GPCR signalling works more broadly within animals, Merritt says.

The team's research was supported by the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada.

Visit link:
Researchers crack 30-year-old mystery of odour switching in worms - University of Toronto

Posted in Molecular Genetics | Comments Off on Researchers crack 30-year-old mystery of odour switching in worms – University of Toronto

Luke Goldman: Using eDNA to save the Atlantic cod – UMaine News – University of Maine – University of Maine

Posted: August 5, 2022 at 2:34 am

Luke Goldman was working as an ocean rescue lifeguard on the Jersey Shore when he decided that he wanted to study ecology. Now, he has moved up the East Coast to become a marine protector of a different sort: a researcher at the forefront of using eDNA to try and save the Atlantic cod.

After Goldman graduated from high school in his native New Jersey, he attended community college for a few years before applying to the University of Maine. He was attracted to the ample natural spaces that were perfect for a budding ecologist to study and explore, as well as the interdisciplinary nature of the Ecology and Environmental Sciences Program.

It is very easy to collaborate with other departments, Goldman says. Im able to take molecular biology and environmental courses, and philosophy and anthropology courses. I feel like you get those interdepartmental connections.

Goldman was first introduced to the concept of eDNA, where DNA in the environment is used to study the organisms living there, through a Research Learning Experience (RLE) course. The cutting-edge scientific technique immediately piqued his interest.

Its a field in its infancy. Its really only been around for 10 years, and for more specific fields of study like marine biology, its only been used for like five years. Its a frontier field in the sciences right now, Goldman says.

At the end of the course, he asked his professor Peter Avis if he had research opportunities to study eDNA. Avis said he didnt, but his wife Erin Grey, assistant professor of aquatic genetics and manager of the Grey Aquatics Lab, did.

Goldman formally met Grey at a university job fair, and she hired him to work in the lab in October 2021. Grey says that Goldmans strong background in both ecology and molecular biology that interdisciplinary blend that brought Goldman to UMaine in the first place made him a great fit for the eDNA project.

You need to be able to understand both, Grey says. He had that unique combination.

Goldman is working on a project that uses eDNA to determine cod spawning locations in the Gulf of Maine. Atlantic cod have been functionally extinct since the late 19th century due to overfishing and ocean warming. The loss of cod was devastating economically and ecologically for the Gulf of Maine, and the populations havent been able to rebound like some other over harvested species in the region once regulations were put in place. Marine scientists arent sure why, but one theory is that something is going wrong with their spawning. The exact locations and times of cod spawning are not well known in the Gulf of Maine, but may be easier to find with the help of eDNA.

We dont really know where they spawn, Grey says. We know a couple of areas, but its a big gulf and they spawn near the bottom. Since it can be easier to collect eDNA from water samples it might be easier for us to detect it.

Goldman takes water samples from spawning cod in a controlled lab environment and uses a process called qPCR, or quantitative polymerase chain reaction, to pick out specific genes only found in cod. Through the process, primers and probes act like selective magnets for the tiny gene sequence, which are multiplied until they are plentiful enough to be detected.

Depending on how long the DNA takes to amplify, Goldman can figure out whether the sequence of DNA he is looking at is background noise or significant enough to be related to spawning. Cod release great quantities of DNA into the water when theyre spawning, after all.

Hes really sort of taken ownership of the project, Grey says. The PCR assay in the beginning had a few kinks we had to work out and he really hunkered down and troubleshooted all that stuff.

Grey says that Goldmans work with eDNA is promising to detect cod in an area in general, but she also hopes to be able to involve eRNA into the project at some point. RNA are smaller subsets of DNA with specific instructions for, as Grey says, doing something in the moment. A cod makes RNAs in eye cells for making eye proteins, for example, or scale cell RNAs for making scale proteins.

In the same vein, the cod material collected in water samples where the fish are releasing their eggs and sperm will exhibit specific RNA related to spawning.

If we can find RNAs that are related to spawning, that would be game changing for the field, Grey says.

Eventually, researchers aim to be able to give fishermen the ability to collect samples on and send them to a lab to conduct eDNA assays to find cod in the field. Goldman even had the opportunity to go out with the Gulf of Maine Research Institute to see if they could catch any spawning cod in order to collect field samples for testing. They didnt catch any spawning cod that day Goldman said that future researchers will have to see if what he finds in the lab can apply to the field but he had a great day fishing regardless.

Goldman hopes to continue using his eDNA skills to solve complex environmental and ecological problems. His eventual goal is to use what he has learned in the Grey Aquatics Lab about eDNA to study fungi in soils, specifically how fungal communities have shifted in response to applications of synthetic fertilizer and the natural recovery that has occurred since fertilizer application has ceased. He is conducting an internship as an aquatic and wetland ecosystem technician for a Ph.D. student studying groundwater seepage, which he says has definitely reinforced his interest in soil.

Ive always been passionate about growing things and gardening and I want to have a farm some day. I took soil science [with Ivan Fernandez] last semester and I really fell in love.

But first, he says, Weve got to save the cod.

Contact: Sam Schipani, samantha.schipani@maine.edu

See more here:
Luke Goldman: Using eDNA to save the Atlantic cod - UMaine News - University of Maine - University of Maine

Posted in Molecular Genetics | Comments Off on Luke Goldman: Using eDNA to save the Atlantic cod – UMaine News – University of Maine – University of Maine

Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors – Business Wire

Posted: August 5, 2022 at 2:34 am

NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that it has appointed Wendy K. Chung, M.D., Ph.D., to its Board of Directors.

Wendy is a tremendous addition to our Board of Directors. Her extensive clinical experience and deep scientific expertise will be a valued asset as we continue to advance our current product portfolio as well as bring additional candidates into our pipeline. We look forward to learning from her expertise and insights, said Martin Mackay, Ph.D., Chairman and Chief Executive Officer at Rallybio. On behalf of our directors, I am pleased to welcome Wendy to Rallybios Board.

As a clinician, I have seen firsthand the significant unmet need for transformative therapies for patients with severe and rare diseases. I look forward to utilizing my scientific background and prior experience to contribute to the Board and the work of the Rallybio team as the Company continues to advance their current portfolio of product candidates and evaluate potential assets for their pipeline, said Dr. Chung.

About Dr. Chung

Dr. Chung is an accomplished leader in the diagnosis and treatment of rare diseases. She is a board certified clinical and molecular geneticist with more than 20 years of experience in human genetic research. Currently, Dr. Chung is the Kennedy Family Professor of Pediatrics and Medicine at Columbia University Irving Medical Center and the Director of Precision Medicine Resource for the Irving Institute for Translational Research at Columbia University. She has authored over 600 peer reviewed papers and 75 reviews and chapters in medical texts. Dr. Chung currently serves as a member of the Board of Directors of Prime Medicine. In addition, Dr. Chung is a member of the Scientific Advisory Board for Sage Bionetworks, Taysha, Helix, and Regeneron Genetics Center. Dr. Chung holds a Bachelor of Arts in Biochemistry and Economics from Cornell University, a Doctor of Medicine from Cornell University Medical College, a Doctor of Philosophy in Genetics from The Rockefeller University.

About Rallybio

Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Companys mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticuts Technology Incubation Program in Farmington, Connecticut. For more information, please visit http://www.rallybio.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our managements beliefs and assumptions and on currently available information. In some cases, forward-looking statements can be identified by terms such as may, will, should, expect, plan, anticipate, could, intend, target, project, contemplate, believe, estimate, predict, potential or continue or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning Rallybios business development strategy and execution, its commercial planning, and the Companys growth. The forward-looking statements in this press release are only predictions and are based largely on managements current expectations and projections about future events and financial trends that management believes may affect Rallybios business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1 and or 1b clinical trials for RLYB212 and RLYB116, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to identify new product candidates and successfully acquire such product candidates from third parties, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybios filings with the U.S. Securities and Exchange Commission (SEC), including Rallybios Annual Report on Form 10-K for the period ended December 31, 2021, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

View post:
Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors - Business Wire

Posted in Molecular Genetics | Comments Off on Rallybio Appoints Wendy K. Chung, M.D., Ph.D., to Its Board of Directors – Business Wire

Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs – Huron Daily…

Posted: August 5, 2022 at 2:34 am

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

(THE CONVERSATION) Viruses that cause respiratory diseases like the flu and COVID-19 can lead to mild to severe symptoms within the first few weeks of infection. These symptoms typically resolve within a few more weeks, sometimes with the help of treatment if severe. However, some people go on to experience persistent symptoms that last several months to years. Why and how respiratory diseases can develop into chronic conditions like long COVID-19 are still unclear.

I am a doctoral student working in the Sun Lab at the University of Virginia. We study how the immune system sometimes goes awry after fighting off viral infections. We also develop ways to target the immune system to prevent further complications without weakening its ability to protect against future infections. Our recently published review of the research in this area found that it is becoming clearer that it might not be an active viral infection causing long COVID-19 and similar conditions, but an overactive immune system.

The lungs in health and disease

Keeping your immune system dormant when there isnt an active infection is essential for your lungs to be able to function optimally.

Your respiratory tract is in constant contact with your external environment, sampling around 5 to 8 liters (1.3 to 2 gallons) of air and the toxins and microorganisms in it every minute. Despite continuous exposure to potential pathogens and harmful substances, your body has evolved to keep the immune system dormant in the lungs. In fact, allergies and conditions such as asthma are byproducts of an overactive immune system. These excessive immune responses can cause your airways to constrict and make it difficult to breathe. Some severe cases may require treatment to suppress the immune system.

During an active infection, however, the immune system is absolutely essential. When viruses infect your respiratory tract, immune cells are recruited to your lungs to fight off the infection. Although these cells are crucial to eliminate the virus from your body, their activity often results in collateral damage to your lung tissue. After the virus is removed, your body dampens your immune system to give your lungs a chance to recover.

Over the past decade, researchers have identified a variety of specialized stem cells in the lungs that can help regenerate damaged tissue. These stem cells can turn into almost all the different types of cells in the lungs depending on the signals they receive from their surrounding environment. Recentstudieshave highlighted the prominent role the immune system plays in providing signals that facilitate lung recovery. But these signals can produce more than one effect. They can not only activate stem cells, but also perpetuate damaging inflammatory processes in the lung. Therefore, your body tightly regulates when, where and how strongly these signals are made in order to prevent further damage.

While the reasons are still unclear, some people are unable to turn off their immune system after infection and continue to produce tissue-damaging moleculeslong after the virus has been flushed out. This not only further damages the lungs, but also interferes with regeneration via the lungs resident stem cells. This phenomenon can result in chronic disease, as seen in several respiratory viral infections including COVID-19, Middle East Respiratory Syndrome (MERS), respiratory syncytial virus (RSV) and the common cold.

The immune systems role in chronic disease

In our review, my colleagues and I found that many different types of immune cells are involved in the development of chronic disease after respiratory viral infections, including long COVID-19.

Scientists so far have identified one particular type of immune cells, killer T cells, as potential contributors to chronic disease. Also known as cytotoxic or CD8+ T cells, they specialize in killing infected cells either by interacting directly with them or by producing damaging molecules called cytokines.

Killer T cells are essential to curbing the virus from spreading in the body during an active infection. But their persistence in the lungs after the infection has resolved is linked to extended reduced respiratory function. Moreover, animal studies have shown that removing killer T cells from the lungs after infection may improve lung function and tissue repair.

Another type of immune cells called monocytes are also involved in fighting respiratory infections, serving among the first responders by producing virus- and tissue-damaging cytokines. Research has found that these cells also continue to accumulate in the lungs of long COVID-19 patients and promote a pro-inflammatory environment that can cause further damage.

Understanding the immunological mechanisms underlying long COVID-19 is the first step to addressing a quickly worsening public health problem. Identifying the subtle differences in how the same immune cells that protect you during an active infection can later become harmful could lead to earlier diagnosis of long COVID-19. Moreover, based on our findings, my team and I believe treatments that target the immune system could be an effective approach to manage long COVID-19 symptoms. We believe that this strategy may turn out to be useful not only for COVID-19, but also for other respiratory viral infections that lead to chronic disease as well.

This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/long-covid-19-and-other-chronic-respiratory-conditions-after-viral-infections-may-stem-from-an-overactive-immune-response-in-the-lungs-186970.

Visit link:
Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - Huron Daily...

Posted in Virginia Stem Cells | Comments Off on Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs – Huron Daily…

Reds prospect rankings will shift after trade deadline acquisition of 10 players – The Athletic

Posted: August 5, 2022 at 2:29 am

MIAMI Jose Barrero is back in the big leagues, called up before Wednesdays game against the Marlins and in the lineup playing shortstop and batting eighth for the Reds.

Going into each of the last two seasons, Barrero topped the Reds top-prospects list at Baseball America and was widely seen as the Reds shortstop of the future.

Barrero has had two previous big-league stints and struggled to hit both times. His talent kept him atop prospect lists, but he was still seen as the teams shortstop of the future, in part because if it wasnt him, who was it?

Now the answer to that question is difficult, maybe because there are too many options as opposed to not enough.

Barrero started to get some competition, if not directly, but at least in the organization, last year when the team took UCLA shortstop Matt McLain with their first-round draft pick and Elly De La Cruz emerged as the most-talked-about prospect in the system and maybe beyond.

Now? One list had Barrero as the Reds fifth-best prospect and fourth-best shortstop prospect after the addition of four shortstops to the teams farm system at this years trade deadline.

The position was already a strength in the organization with Barrero, De La Cruz, McLain and Jose Torres. Now you can add Noelvi Marte and Edwin Arroyo from the Mariners, Spencer Steer from the Twins and Victor Acosta from the Padres.

I do believe the Reds now have the best collection of shortstops in the minors, Baseball America editor-in-chief J.J. Cooper told The Athletic. Thats important to me because shortstops are the stem cells of a rebuild, since they have the versatility to turn into almost anything you need them to be. Shortstops become third basemen and second basemen, they become center fielders and corner outfielders. I have zero confidence in projecting who will be the Reds MLB shortstop in 2024 because they have so many options, but I have a lot of confidence that the Reds lineup should be filled with ex-shortstops playing other positions.

Seven of Baseball Americas recently updated Top 100 prospects were traded in the week leading up to the trade deadline three went to the Reds, three to the Nationals and one to the Angels. The Reds acquired the most minor-league players of any team with 10.

The Athletics Keith Law called the Reds one of the deadlines winners, just after the Padres. He also had three Reds in his updated Top 60 prospect list: De La Cruz at No. 8, Marte at No. 12 and the teams first-round pick, Cam Collier, at No. 29. Law also included Arroyo among 10 honorable mentions on his Top 60 list.

They added a slew of high-upside prospects, and while they wont all work out, theyve acquired so many of those guys at this point that theyre likely to get two or three stars out of the entire system, including the players they already had, Law said. When you add to that the fact that theyve had two very solid drafts in 2021-22, and some of the young players still developing in MLB, they seem like theyre in way better shape going forward than they were even four months ago.

Cooper said Baseball America is working on updating its team Top 30 prospect lists and is having to search for those last five prospects in some systems. For the Reds, there are players he sees as big-league contributors who arent even among the Top 30.

After conferring with scouts, executives and writers, heres a look at the Reds Top 10 prospects before the season from The Athletic and Baseball America and a projected 2023 preseason list taking into account graduations by Barrero, Hunter Greene, Nick Lodolo and Graham Ashcraft:

Reds Top 10 prospects lists

Hunter Greene

Jose Barrero

Elly De La Cruz

Elly De La Cruz

Hunter Greene

Noelvi Marte

Matt McLain

Nick Lodolo

Edwin Arroyo

Jay Allen II

Elly De La Cruz

Spencer Steer

Nick Lodolo

Matt McLain

Cam Collier

Graham Ashcraft

Austin Hendrick

Matt McLain

Mat Nelson

Jay Allen II

Brandon Williamson

Jose Torres

Rece Hinds

Connor Phillips

Rece Hinds

Graham Ashcraft

Andrew Abbott

Andrew Abbott

Bryce Bonnin

Levi Stoudt

Of those top 10, only three were in the system when the previous lists were published. Pitchers Brandon Williamson and Connor Phillips came over this spring in the deal with Seattle that sent Jesse Winker and Eugenio Surez to the Mariners. McLain and Abbott were both drafted in 2021 and De La Cruz wasnt on anyones radar at the start of 2021.

Its nearly a completely different system, but one that should be ranked much higher than it was before.

With that noted, heres a look at the 10 players (not including the player to be named acquired for Tommy Pham) the Reds received at the trade deadline, with information collected from various sources around the game:

SS Victor Acosta (from Padres): Acosta was one of the Padres top international signings a year ago and was with their Arizona Rookie League team. The 18-year-old is seen as a player who can play multiple positions with good defense and a plus arm.

RHP Jos Acua (from Mets): The 19-year-old right-hander made his organizational debut Tuesday night for Single-A Daytona against his old St. Lucie teammates, going five innings, allowing an unearned run on four hits with six strikeouts, no walks and a hit batter.

SS Edwin Arroyo (from Mariners): Arroyo wont be 19 until later this month, but hes already put up a .316/385/.514 slash line with 13 home runs in 87 games at Single-A Modesto. Hes also played a pair of games with the Reds Arizona Complex League team and will report to Daytona soon. One rival team official said his team had Arroyo as the Mariners No. 1 prospect before the deal. A switch hitter and switch thrower, Arroyo is a true shortstop and of the players acquired at the deadline, may have the best chance to stick at short.

3B Christian Encarnacion-Strand (from Twins): A corner infielder, Encarnacion-Strand played at Oklahoma State for Robin Ventura and Matt Holliday. Those two are influences on the way he plays, one source noted. Encarnacion-Strand has big-time power, hitting 20 homers in 74 games at High A and five at Double A in just 13 games.

LHP Steve Hajjar (from Twins): A classic four-pitch lefty, Hajjar averages around 91 mph on his fastball, but it plays up with good carry. His slider, curve and change are all solid average. The Twins believed he had a good chance to start in the big leagues.

SS Noelvi Marte (from Mariners): The highest-ranked prospect, Marte announced his presence with authority Wednesday with a pair of homers for High A Dayton. Overall, hes hitting .274/.360/.473 with 17 home runs and 19 doubles. Some think he may move to third base, but he does have a chance to stick at short. Regardless of where he plays in the field, the bat is his calling card.

RHP Andrew Moore (from Mariners): A 6-foot-5 right-hander, Moore was taken out of Chipola Junior College in the 2014 draft. Moores fastball hits triple digits and has a hard slider. Hes dominated in Single A, where he struck out 58 batters in 32.1 innings, walking 17.

OF Hector Rodriguez (from Mets): The 18-year-old has played in the infield this season with the Mets complex team, but the Reds see him as a pure center fielder, with excellent speed. He had 12 steals in 26 games for the Mets Florida Complex Team and had two in his first two games for the Reds complex team.

SS Spencer Steer (from Twins): Steer could be the first of the players acquired to reach the big leagues. A right-handed thrower and hitter, hes played shortstop but probably projects more as a corner infielder. One scout compared Steer to Brandon Drury, a solid hitter who can play around the infield.

RHP Levi Stoudt (from Mariners): A four-pitch pitcher, Stout has a mid-90s fastball that can get up to 98 mph. He has a hard slider that can be above average, as well as a curveball and changeup. Stout was in Double A for the Mariners and has already reported to Double-A Chattanooga.

(Photo of Spencer Steer: Ed Bailey / Wichita Wind Surge)

See the rest here:
Reds prospect rankings will shift after trade deadline acquisition of 10 players - The Athletic

Posted in Arizona Stem Cells | Comments Off on Reds prospect rankings will shift after trade deadline acquisition of 10 players – The Athletic

Man who saved life as stem cell donor urges others to help his friend find a match after five-year search – Lancashire Evening Post

Posted: August 5, 2022 at 2:27 am

Alex Christopher, 34, who lives in Brinscall, donated his cells over three years ago when he signed on the donor register in a bid to help his friend and colleague Peter McCleave, 40.

He might not have been a match for his friend, but for Patrick Languzzi who lives in Boston, Massachusetts, in America, Alex proved to be a life-saver.

Patrick had been diagnosed with a rare blood cancer and given a three per cent chance of survival.

In January this year the pair met for the first time over a Zoom call where Alex told Patrick of his friend's plight and both gents made a pact to help gain more donors.

Peter, who was diagnosed with myeloma in 2017 and told that he has seven years to find a match for a lifesaving stem cell donation, set up a campaign to collect an initial 10,000 donors and is now targeting 100,000.

Why did Alex sign up?

Alex, who works for the investment arm of Natwest, said: "I signed up on a whim to help my friend Peter but sadly I was not a match.

"Peter is still looking for his match as a lot of people think 'it won't be me' and I held the same mindset until it was.

"You have the power to change an individual's life and not just theirs but also their family and friends.

"I have seen first hand the effect it has had on Patrick's friends.

"I was a 100 per cent match for Patrick and someone that maybe hasn't registered could be the same for Peter."

Although it was sad circumstances that brought him Alex on his journey, the father of one said all three men have formed a group chat and speak all the time.

"We attended the DKMS London Gala in May together and raised 1.5 million, said the former Lancaster Royal Grammar School pupil from Morecambe.

"It was very strange with models and influencers and some pledging 10,000."

What does Alex say to people afraid to sign up?

Alex explains he did not have to undergo any painful or invasive procedures - his stem cells were extracted from blood taken intravenously at a private clinic in London, then the blood was returned to him, equating to three hours and 45 minutes.

"I would say to people just do it as the more people who sign up the better the odds are for the people waiting on their matches.

"It is so straight forward and easy."

Speaking highly of Peter, Alex added that even though he has been waiting a long time for his genetic twin to come along as he has a very specific DNA composite.

"For him to get a match would be a nice end, but he wouldn't stop going as he would want to continue helping others.

How can you sign up to be a stem donor?

DKMS is a blood cancer charity based in London that registers blood stem donors. Every 20 minutes someone in the UK is diagnosed with a blood cancer and for many a blood stem donation is their best chance of survival.

Read the original:
Man who saved life as stem cell donor urges others to help his friend find a match after five-year search - Lancashire Evening Post

Posted in Massachusetts Stem Cells | Comments Off on Man who saved life as stem cell donor urges others to help his friend find a match after five-year search – Lancashire Evening Post

The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) – Digital Journal

Posted: August 5, 2022 at 2:27 am

The increasing focus on discovering alternatives to animal testing, the expanding focus on customized therapy, the rising incidence of chronic diseases, and the availability of research funding are all driving 3D cell culture market forward. However, over the projection period, the absence of infrastructure for 3D cell-based research and the high cost of cell biology research are projected to limit the markets growth.Testing on animals has been the most common technique in various experimental trial studies in biomedical research because they resemble humans in terms of genetics, anatomy, and physiology. Mice genome structure Is 80% similar to humans, which makes them excellent replicas for various research works. On the other hand, the use of animals in scientific research is associated with several ethical concerns, which led to the formation of the code of 3Rs- Reduction, Replacement, and Refinement, to address the moral concerns related to animal wellbeing and limit the use of animals in scientific research.

As of 2018, this initiative led to a 50% decrease in the use of animals as compared to the statistics from 1985. Additionally, the practice of animal breeding housing for scientific purposes is also associated with high costs and needs skilled labor. Furthermore, it has been confirmed that animal cell cultures are unable to precisely mimic the natural (in vivo) microenvironment as the cells cultured in monolayers are both morphologically and physiochemical different from their in vivo counterparts. These concerns have demanded a transition from animal testing to the use of 3D cell culture models. Over time the advancement in biotechnology and materials science has enabled the development of a variety of 3D cell culture systems to determine the research across different areas, including cancer research, drug discovery, tissue engineering, and others.

Click Here to Download and Understand Latest Key Trends On Global 3D Cell Culture Market

https://skyquestt.com/sample-request/3d-cell-culture-market

More than 140 companies offer 3D cell culture systems at present in a variety of formats, which includes scaffold-based products, scaffold-free products, and 3D bioreactors. These systems have been confirmed to be capable of more precisely simulating the natural tissue microenvironment, offering increased cell to cell and cell to ECM connections, more precise evaluation of drug toxicity and cellular responses, and culturing multiple cell types together. Furthermore, there are definite complex 3D cell culture models that can even replace animal models demonstrating reproducible results and thus, serving as better in-vivo models across multiple applications. Given the various benefits of such systems, the field has gathered the attention of various VC firms and strategic investors that have been providing monetary support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ on chips across multiple use case. Additionally, there has been an increase in the scientific works on 3D cell culture systems and partnerships for 3D bioreactors and cell culture products. Given the current innovation in this field and the pattern shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness significant growth in the predicted future.

The North American region accounted for the highest revenue share of over 43% and led the global 3D cell culture market in 2020. The region will hold its leading position throughout the forecast period. The availability of private and government funding for the innovation of advanced 3D cell culture models accounts for this growth in the region. High healthcare spending and the presence of numerous universities and research organizations investigating various stem cell-based methods push the growth in the sector. Researchers from Mayo Clinic and Terasaki Institute in the US developed visible hydrogels that can be used for the monitoring and control of hemorrhage, in December 2020. Asia Pacific is likely to grow at the fastest CAGR in the global 3D cell culture market and is likely to continue the same trend during the forecast period. This is attainable due to growing investments by several companies and rising healthcare spending in developing economies like China and India in the region. Also, government support & planned initiatives are expected to support the growth of the market in near future.Read the market research report, The Global 3D cell culture Market is segmented By Product (Scaffold-Based 3D cell culture, Scaffold-Free 3D cell culture, Microfluidics, and 3D Bioreactors), By Application (Drug Discovery, Tissue Engineering, Cancer Treatment, Regenerative medicine, Clinical, and Other Applications), By End User (Research Laboratories and Institutes, Biotechnology and Pharmaceutical Companies and Academic Institutes) & By Region- Forecast and Analysis 2021-2027. by SkyQuest

As a result of the domains technological nascence, no company currently wields significant influence, and the race to dominance has already begun, with companies investing in multiple 3D Cell Culture projects, acquiring a few on their way to the finish line in the domain. The top players in this market include 3D Biotek LLC (US), Advanced Biomatrix Inc. (US), Avantor Inc. (US), Becton, Dickinson, and Company (US), Corning Incorporated (US), Lonza Group (Switzerland), InSphero AG (Switzerland), Merck & Co., Inc (US), Synthecon Inc. (US), Thermo Fisher Scientific Inc. (US).

The report published by SkyQuest Technology Consulting provides in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions.

Speak with our analyst for more information:

https://skyquestt.com/speak-with-analyst/3d-cell-culture-market

SkyQuest has segmented the Global 3D Cell Culture Market based on Product, Application, End-User, and Region: 3D Cell Culture Product Outlook (Revenue, USD Million, 2021 2027)o Scaffold-Based 3D cell cultureo Scaffold-Free 3D cell cultureo Microfluidicso 3D Bioreactors 3D Cell Culture Application Outlook (Revenue, USD Million, 2021 2027)o Drug Discoveryo Tissue Engineeringo Cancer Treatmento Regenerative medicineo Clinical, and Other Applications 3D Cell Culture End-User Outlook (Revenue, USD Million, 2021 2027)o Research Laboratories and Instituteso Biotechnology and Pharmaceutical Companieso Academic Institutes 3D Cell Culture Regional Outlook (Revenue, USD Million, 2021 2027)o North America U.S. Canadao Europe Germany France UK Italy Spain Rest of Europeo Asia Pacific China India Japan Rest of Asia Pacifico Central & South America Brazil Rest of CSAo Middle East & Africa GCC Countries South Africa Rest of MEA

List of Key Players of the 3D Cell Culture Market 3D Biotek LLC (US) Advanced Biomatrix Inc. (US) Avantor Inc. (US) Becton, Dickinson, and Company (US) Corning Incorporated (US) Lonza Group (Switzerland) InSphero AG (Switzerland) Merck & Co., Inc (US) Synthecon Inc. (US) Thermo Fisher Scientific Inc. (US)

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:[emailprotected]

Find Insightful Blogs/Case Studies on Our Website:

Market Research Case Studies

Read the original post:
The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) - Digital Journal

Posted in Massachusetts Stem Cells | Comments Off on The 3D Cell Culture Market is expected to reach a value of USD 3721.86 Million by 2027, at a CAGR of 13.4% (2021 2027) – Digital Journal

Horror stories of cryonics: The gruesome fates of frozen bodies – Big Think

Posted: August 5, 2022 at 2:24 am

Several facilities in the U.S. and abroad maintain morbid warehouse morgues full of frozen human heads and bodies, waiting for the future. They are part of a story that is ghoulish, darkly humorous, and yet endearingly sincere. For a small group of fervent futurists, it is their lottery ticket to immortality. What are the chances that these bodies will be reanimated? Will baseball legend Ted Williams frozen head be awakened to coach fighter pilots or fused to a robot body to hit .400 again?

Cryonics attempting to cryopreserve the human body is widely considered a pseudoscience. Cryopreservation is a legitimate scientific endeavor in which cells, organs, or in rare cases entire organisms may be cooled to extremely low temperatures and revived somewhat intact. It occurs in nature, but only in limited cases.

Humans are particularly difficult to preserve because of the delicate structure in (most of) our heads. Deprived of oxygen at room temperature, the brain dies within minutes. While the body may be reanimated, the person who lives is often in a permanent vegetative state. Cooling the body may give the brain a bit more time. During brain or heart surgery, circulation may be stopped for up to an hour with the body cooled to 20 C (68 F). A procedure to cool the body to 10 C (50 F) without oxygen for additional hours is still at the experimental research stage.

After a while, he let the bodies thaw out inside the capsule and left the whole thing festering in his vault.

When a cryonic patient dies, a race begins to prepare and cool the body before it decays and then to place it inside a Dewar: a thermos bottle full of liquid nitrogen (LN). The inner vessel of the Dewar contains a body, or bodies, wrapped in several layers of insulating material, attached to a stretcher, and suspended in LN. The head is oriented downward to keep the brain the coldest and most stable.

This vessel lies within a second outer vessel, separated by a vacuum to avoid heat transfer from the outer room-temperature vessel wall to the cold inner vessel wall. Heat gradually transfers across anyway and boils away the LN, which must be periodically refilled. Bodies were originally, and may still be in some cases, cooled and frozen in whatever condition they were in at death, with better or worse preservation, as we shall see.

The early years of cryonics were grisly. All but one of the first frozen futurists failed in their quest for immortality.

Subscribe for counterintuitive, surprising, and impactful stories delivered to your inbox every Thursday

Small freezing operations began in the late 1960s. While the practice of storing bodies has become more sophisticated over the past 50 years, in the early days, technicians cooled and prepared corpses with haste on dry ice before eventually cramming them into Dewar capsules. By in large, these preservations did not achieve preservation. They were nightmarish, gruesome failures. Their stories were researched and documented by people within the field, who published thorough and frank records.

The largest operation was run out of a cemetery in Chatsworth, California by a man named Robert Nelson. Four of his first clients were not initially frozen in LN but placed on a bed of dry ice in a mortuary. One of these bodies was a woman whose son decided to take her body back. He hauled (his dead mother) around in a truck on dry ice for some time before burying her.

The bodies in the container partially thawed, moved, and then froze again stuck to the capsule like a childs tongue to a cold lamp post.

Eventually, the mortician was not pleased with the other bodies sitting around on beds of ice, so a LN Dewar capsule was secured for the remaining three. Another man was already frozen and sealed inside the capsule, so it was opened, and he was removed. Nelson and the mortician then spent the entire night figuring out how to jam four people who may or may not have suffered thaw damage into the capsule. The arrangement of bodies in different orientations was described as a puzzle. After finding an arrangement that worked, the resealed capsule was lowered into an underground vault at the cemetery. Nelson claimed to have refilled it sporadically for about a year before he stopped receiving money from the relatives. After a while, he let the bodies thaw out inside the capsule and left the whole thing festering in his vault.

Another group of three, including an eight-year-old girl, was packed into a second capsule in the Chatsworth vault. The LN system of this capsule subsequently failed without Nelson noticing. Upon checking one day, he saw that everyone inside had long thawed out. The fate of these ruined bodies is unclear, but they might have been refrozen for several more years.

Nelson froze a six-year-old boy in 1974. The capsule itself was well maintained by the boys father, but when it was opened, the boys body was found to be cracked. The cracking could have occurred if the body was frozen too quickly by the LN. The boy was then thawed, embalmed, and buried. Now that there was a vacancy, a different man was placed into the leftover capsule, but ten months had elapsed between his death and freezing, so his body was in rotten shape no pun intended from the get-go and was eventually thawed.

Every cryonic client put into the vault at Chatsworth and looked after by Nelson eventually failed. The bodies inside the Dewar capsules were simply left to rot. Reporters visited the crypt where these failed operations had taken place and reported a horrifying stench. The proprietor admitted to failure, bad decisions, and going broke. He further pointed out, Who can guarantee that youre going to be suspended for 10 or 15 years?

The worst fates of all occurred at a similar underground vault that stored bodies at a cemetery in Butler, New Jersey. The storage Dewar was poorly designed, with uninsulated pipes. This led to a series of incidents, at least one of which was failure of the vacuum jacket insulating the inside. The bodies in the container partially thawed, moved, and then froze again stuck to the capsule like a childs tongue to a cold lamp post. Eventually the bodies had to be entirely thawed to unstick, then re-frozen and put back in. A year later, the Dewar failed again, and the bodies decomposed into a plug of fluids in the bottom of the capsule. The decision was finally made to thaw the entire contraption, scrape out the remains, and bury them. The men who performed this unfortunate task had to wear a breathing apparatus.

Out of all those frozen prior to 1973, one body remains preserved. Robert Bedford was sealed into a Dewar in 1967. Instead of leaving the body to meet a horrific fate under Nelsons care, Bedfords family took custody of the capsule, meticulously caring for it at their own expense. The body was handed off between professional cryonics operations, occupying multiple frozen tanks and facilities for 15 years or so. Eventually it ended up in the hands of the founders of Alcor a modern cryonics outfit one of whom wrote a heartfelt, slightly creepy piece about the body.

Credit: Jeff Topping / Getty Images

Alcor is the leading example of the current state of cryonics. While the ugly events above suggest that your remains might well end up as tissue sludge scraped out of a can, the professionalism of companies like Alcor may offer an increased chance for long-term preservation. This 501(c)(3) organization hosts researchers who work on methods to improve the freezing process, possibly increasing whatever slight odds exist that human popsicles will ever be brought back to life. At a more fundamental level, it appears to be stable and to have deep pockets, so there is a better chance that your corpse will be around long enough for some distant future doctor to recoil in horror at it.

The U.S. industry has consolidated around two main organizations. If not Alcor, your other choice is the Cryonics Institute, which has more than 200 bodies stored in giant tanks and accepts dozens more each year. Apparently, ten years ago, head storage alone at Alcor cost $80,000, while full body storage at the Cryonics Institute was only $30,000. There are international options as well. A Russian cryogenics company stores not only people but pets, including one entry under rodents, a deceased chinchilla named Button.

Modern cryonic preparations at Alcor employ a multistep process to prepare the body for storage. First, they begin to cool the body while anti-clotting agents and organ preservation solutions are injected into the bloodstream and circulated under CPR. The body is then transported to the companys main facility, where the original fluid is replaced with chemicals that vitrify turn to glass the bodys organs. This offers some hope for cutting down on structural damage during the subsequent cooling and storage. Then the body is entombed in its Dewar capsule.

That all sounds scientific and careful. But is it really science or just applying scientific tools to a fantasy proposition? Is it possible to freeze the human body and revive it decades later? Currently, its not remotely plausible. Will it ever be? Thats probably an open question. As it stands now, cryonics is a bizarre intersection of scientific thinking and wishful thinking.

Credit: Annelisa Leinbach / Big Think

While cryonic preparation is now more advanced, the laws of physics demand that the structure of the body will break down rapidly after death, catastrophically upon freezing, and gradually over time, even while frozen. Think of how badly frozen food ages in your freezer. If the medical technology of the future becomes advanced enough, perhaps these corpses can be revived. But thats a big if. Lets say your body remains frozen until the 25th century. Then, lets say that future doctors are interested in reviving you. How much work will they have to do to fix you once youre thawed? The answer lies in the condition of the bodies once theyre thawed. Strangely enough, we know something about this.

In 1983, Alcor needed to lighten three cryonauts, reducing them from bodies to simply heads. (In one transhumanist conception of the future, medical science will be able to revive the brain and then simply make a new body or robot to which to attach it. Neuropreservation is cheaper and easier too.) The three corpses were removed from their Dewar capsules so that the heads could be cut off still frozen, so requiring a chainsaw and stored separately. Once the heads were sawed off and put away, Alcor employees got to work medically examining the state of the bodies. They wrote up their findings in great detail.

At first, things looked reasonably good. While the bodies were still frozen, their skin was only moderately cracked in a few places. But once the bodies thawed, things started to go downhill.

The organs were badly cracked or severed. The spinal cord was snapped into three pieces and the heart was fractured.

Cracks appeared in the warming bodies, cutting through the skin and subcutaneous fat, all the way down to the body wall or muscle surface beneath. One patient displayed red traces across the skin following the paths of blood vessels that ruptured. Two of the patients had massive cutaneous ruptures over the pubis. The soft skin in these areas was apparently quite susceptible to cracking.

While the external damage was extensive, the internal damage was worse. Nearly every organ system inside the bodies was fractured. In one patient, every major blood vessel had broken near the heart, the lungs and spleen were almost bisected, and the intestines fractured extensively. Only the liver and kidneys werent completely destroyed.

The third body, which had been thawed very slowly, was in better condition externally, with only a few skin fractures and no obvious exploded blood vessels. However, the inside was even more annihilated than the others. The organs were badly cracked or severed. The spinal cord was snapped into three pieces and the heart was fractured. The examiners injected dye into an artery in the arm. Rather than flow through blood vessels and into muscles, most of it pooled under the surface in pockets and leaked out of skin fractures.

The medical examiners extensively detailed the content of the blood, the texture of the muscles, and the extent of the damage. They included pictures. And they earnestly stated their conclusion up front: The tremendous tissue deterioration will require incredibly advanced medical technology to fix. Worse, the probable destruction at the cellular level may require rebuilding the body at the molecular level. Perhaps future medicine might be able to inject swarms of nanobots into your body to repair every bit of tissue, but dont bet on it happening any time soon.

Modern cryonics practices may ward off the horrific failures of the past. And we cant entirely rule out future medicine somehow finding fixes for the terrific damage incurred by the body in freezing, sitting, and thawing. But theres one more hurdle for the future revivification of your frozen form, the last great danger to your immortality: your crazy relatives. Several cases demonstrate the problem.

The family of a man frozen in 1978 eventually got tired of paying for him. The facility offered to cut off his head and store it for free, but the family turned them down. Instead, the body was thawed, submerged in a vat of formaldehyde like a laboratory specimen, and buried in that condition. Two further men were stored by their sons, one of whom had his father thawed, removed, and buried. The other son eventually buried his dads capsule in its entirety with the remains still inside.

Relatives can also go to court and battle over what happens to your corpse. Richard Orvilles family buried him against his wishes and was eventually forced by an Iowa court to dig up his body for preservation. A Colorado womans family went to court to fight Alcor for their mothers head. Alcor eventually got the head, to preserve as best they could. Conversely, another womans will stated that she did not want to be frozen. Her husband froze her anyway, and after a four-year court battle, the State of California ordered that she be thawed and buried.

One particularly well-known family affair is the story of a frozen Norwegian man who was initially stored at a California facility that worked with Alcor. He was removed by his daughter, who stored him in an ice shed behind her house in Colorado. The body was discovered when she was evicted from the property. The small town of Nederland, Colorado now has a Frozen Dead Guy Days celebration every year.

While the chances of immortality may be slim, dozens of people still commit their bodies or brains to cryonics each year. If their remains arent mismanaged or allowed to disintegrate, and if their relatives dont go to court over the body, there is now a good chance that they will remain frozen for decades. Unfortunately, they will come out of the process cracked into a million pieces, and the prospect of putting them back together again is purely science fiction for the foreseeable future. Its a grim practice with ghoulish results; at least it makes for some fascinating stories and a bit of dark humor.

Continued here:
Horror stories of cryonics: The gruesome fates of frozen bodies - Big Think

Posted in Transhumanist | Comments Off on Horror stories of cryonics: The gruesome fates of frozen bodies – Big Think

Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results – GuruFocus.com

Posted: August 5, 2022 at 2:23 am

CAMBRIDGE, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. ( GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and second quarter 2022 financial results.

We are advancing our leading non-viral genetic medicine platform to unlock the potential of durable, redosable non-viral DNA therapeutics, and we have made significant progress in establishing the proprietary technologies necessary to realize our vision, said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. This quarter, process development and scaling of rapid enzymatic synthesis (RES) for production of our closed-ended DNA (ceDNA) construct has allowed us to pursue a more flexible and capital efficient manufacturing strategy. In the remainder of the year, we plan to continue to develop our unique cell-targeted lipid nanoparticle (ctLNP) system for systemic delivery to hepatocytes, as well as for other therapeutic areas such as the retina and vaccines.

Business Highlights

Second Quarter 2022 Financial Results

About Generation BioGeneration Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The companys non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific cell types, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bios manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.

For more information, please visit http://www.generationbio.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the company, including statements about the companys strategic plans or objectives, manufacturing plans, cash resources, technology platform, including RES, research and clinical development plans, and preclinical data and other statements containing the words believes, anticipates, plans, expects, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties inherent in the identification and development of product candidates, including the conduct of research activities, the initiation and completion of preclinical studies and clinical trials and clinical development of the companys product candidates; uncertainties as to the availability and timing of results from preclinical studies and clinical trials; whether results from earlier preclinical studies will be predictive of the results of later preclinical studies and clinical trials; uncertainties regarding the RES manufacturing process; uncertainties regarding the companys ability to assign or sublease its manufacturing property; whether the changes to the companys manufacturing strategy will achieve the anticipated savings; challenges in the manufacture of genetic medicine products; whether the companys cash resources are sufficient to fund the companys operating expenses and capital expenditure requirements for the period anticipated; the impact of the COVID-19 pandemic on the companys business and operations; expectations for regulatory approvals to conduct trials or to market products; as well as the other risks and uncertainties set forth in the Risk Factors section of the companys most recent annual report on Form 10-K and quarterly report on Form 10-Q, which are on file with the Securities and Exchange Commission, and in subsequent filings the company may make with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the companys views as of the date hereof. The company anticipates that subsequent events and developments will cause the companys views to change. However, while the company may elect to update these forward-looking statements at some point in the future, the company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the companys views as of any date subsequent to the date on which they were made.

Investors and Media ContactMaren KillackeyGeneration Bio[emailprotected]857-371-4638

GENERATION BIO CO.CONSOLIDATED BALANCE SHEET DATA (Unaudited)(In thousands)

GENERATION BIO CO.CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)(in thousands, except share and per share data)

Follow this link:
Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results - GuruFocus.com

Posted in Genetic medicine | Comments Off on Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results – GuruFocus.com

Page 250«..1020..249250251252..260270..»